Magnitude of benefit of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for malignant tumor: A meta-analysis
-
Published:2020-03
Issue:
Volume:147
Page:102888
-
ISSN:1040-8428
-
Container-title:Critical Reviews in Oncology/Hematology
-
language:en
-
Short-container-title:Critical Reviews in Oncology/Hematology
Author:
Gu LihuORCID,
Du Nannan,
Jin Qiong,
Li Shengnan,
Xie Laidi,
Mo Jiahang,
Shen Zefeng,
Mao Danyi,
Ji Jia,
Khadaroo Parikshit Asutosh,
Chen BangshengORCID
Subject
Oncology,Hematology
Reference35 articles.
1. Understanding the mismatch between the demands of risk assessment and practice of scientists--the case of Deca-BDE;Alcock;Environ. Int.,2011
2. The PARP superfamily;Ame;Bioessays,2004
3. Randomized, double-blind phase II trial with prospective classification by ATM protein level to evaluate the efficacy and tolerability of olaparib plus paclitaxel in patients with recurrent or metastatic gastric Cancer;Bang;J. Clin. Oncol.,2015
4. Targeting homologous repair deficiency in breast and ovarian cancers: biological pathways, preclinical and clinical data;Chartron;Crit. Rev. Oncol. Hematol.,2019
5. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial;Clarke;Lancet Oncol.,2018
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献